slides · global inventory
Plan Implementation
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 6,044
Current window 4,171-4,200
Pages 202
Rows per page 30
Slide function
4,171-4,200 of 6,044
10
a.k.a. Brands | Investor Presentation Deck | 21 slidesa.k.a. Brands | Investor Presentation Deck | 21 slides · a.k.a. Brands
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
11
a.k.a. Brands | Investor Presentation Deck | 21 slidesa.k.a. Brands | Investor Presentation Deck | 21 slides · a.k.a. Brands
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
12
The map shows specific store locations with opening dates and square footage.a.k.a. Brands | Investor Presentation Deck | 21 slides · a.k.a. Brands
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style chart to show the development stage of multiple drug candidates.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a timeline-based framework to categorize R&D milestones and market opportunities.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
15
Focuses on PRO (Patient Reported Outcomes) as a primary endpoint for the EBO-301 trial.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
21
The slide uses a dual-track timeline approach to show the progression from observational data collection to clinical trial phases.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
08
The slide highlights both existing drug expansion and new drug development milestones.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Aha Moment1 hit
23
The slide outlines a multi-year capital investment plan for satellite constellation expansion.Eutelsat | Results Presentation Deck | 27 slides · Eutelsat Group
Conference presentation Investor relations Beat · VisualizationLoop · Cost Of Inaction1 hit
04
The slide uses a timeline framework to map clinical trial progress against calendar periods.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
05
The chart uses a Gantt-style visualization to represent clinical trial progress.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
13
The slide outlines a multi-arm clinical development strategy with standardized trial designs (Part A/B) across different indications.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
18
The slide outlines a two-part study design (Part A: Randomized/Double-Blind, Part B: Open-Label Extension) with specific patient counts and dosing regimens.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
19
The slide outlines two study arms (MM120 ODT 100 µg and Placebo) with a primary endpoint at week 6, followed by a 40-week extension.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
22
The central diagram is a circular hub-and-spoke model representing the MM120 Value Proposition.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
25
The slide uses a structured table to map clinical workflow to billing codes.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
27
The slide outlines two parallel studies (Voyage and Panorama) with specific participant counts and dosing regimens.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
28
The slide uses a structured list format to map specific clinical trial risks to mitigation strategies.MindMed | Investor Presentation Deck | 28 slides · MindMed
Pitch deck Investor relations 1 hit
05
The chart uses a Gantt-style visualization to represent clinical trial progress.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · RoadmapLoop · Golden Circle1 hit
06
The slide uses a horizontal timeline format to track clinical trial milestones.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · RoadmapLoop · Golden Circle1 hit
11
Shows specific trial names (Voyage, Panorama, Emerge), sample sizes, randomization, and study phases.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
15
The slide outlines the clinical development strategy for a drug candidate, emphasizing continuity from Phase 2b to Phase 3.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Loop · Golden Circle1 hit
18
The slide outlines two distinct study protocols with specific sample sizes and dosing regimens, including a primary endpoint at week 12.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
20
Shows a process flow between follow-up observation and potential treatment based on clinical criteria.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
25
The slide outlines a clinical trial protocol with a primary endpoint at week 6 and a 40-week extension phase.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
26
Includes study timeline, randomization details, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
28
The slide emphasizes regulatory alignment and standard clinical trial methodology.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
29
Includes study arms, dosing, follow-up timeline, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
17
Nextdoor | Investor Presentation Deck | 36 slidesNextdoor | Investor Presentation Deck | 36 slides · Nextdoor
Pitch deck Investor relations Beat · Business Model1 hit